UBE3A gene therapy (Asklepios BioPharmaceutical/University of North Carolina)

N/A

Report date: 2025/01/26 16:35:33

Base Information

Drug NameUBE3A gene therapy (Asklepios BioPharmaceutical/University of North Carolina)
Drug Alias NameUBE3A gene therapy (Asklepios BioPharmaceutical)UBE3A gene therapy (Asklepios BioPharmaceutical/University of North Carolina)adeno-associated viral vector based UBE3A gene therapy (Asklepios BioPharmaceutical/University of North Carolina)
ClassificationBiologics
Mechanisms of ActionUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina, Greensboro
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of North Carolina, GreensboroAskBio Inc
Inactive CompaniesN/A
Active IndicationsAngelman Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A